BeyondAirInc . (NASDAQ:XAIR) posted its quarterly earnings results on Monday. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.01), MarketWatch Earnings reports. The firm had revenue of ($0.20) million for the quarter, compared to analysts’ expectations of $0.45 million. BeyondAirInc . had a negative net margin of 203.22% and a negative return on equity of 208.33%.
Shares of XAIR stock opened at $6.95 on Thursday. The stock has a market cap of $125.82 million, a PE ratio of -3.78 and a beta of -0.60. The business has a 50-day simple moving average of $7.39 and a 200-day simple moving average of $6.69. BeyondAirInc . has a 52-week low of $3.45 and a 52-week high of $12.50.
XAIR has been the topic of several research analyst reports. Oppenheimer reiterated a “buy” rating and set a $9.00 price target on shares of BeyondAirInc . in a research note on Tuesday. Zacks Investment Research reiterated a “buy” rating and set a $9.25 price target on shares of BeyondAirInc . in a research note on Saturday, May 30th. Finally, ValuEngine upgraded BeyondAirInc . from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd.
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.
Further Reading: What is a front-end load?
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.